Skip to content

Ketamine research published in 2026

Page 34 of 35: studies 661 to 680 of 699, newest first. Back to the ketamine overview

Studies

Culinary-Medicinal Lion's Mane Mushroom Hericium erinaceus (Agaricomycetes) Mycelium Mitigates Ketamine Abuse Potential

International journal of medicinal mushrooms 2026 Mei-Yi Lee, Yung Ting Hung, Yu-Ching Hsiao et al.

Ketamine therapy is effective in alleviating symptoms of psychiatric disorders such as depression and anxiety; however, its increasing recreational use raises concerns about potential abuse. Hericium erinaceus mycelium, which contains the bioactive compound erinacine A, has shown promise in promoting brain health. This study investigated whether H. erinaceus mycelium and erinacine A could...

Rapid Symptom Reduction Following Intramuscular Ketamine in Refractory Obsessive–Compulsive Disorder: A Case Report

Case Reports in Psychiatry 2026 Maxwell Angel

Introduction: Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition that frequently presents with comorbid depressive disorders. For patients exhibiting treatment-refractory OCD and concurrent depressive disorder(s), there is growing clinical interest in the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine as a rapid-acting intervention. This case report...

Translational Regulation in Excitatory Neurons Controls Stress Reactivity and the Antidepressant Response to Ketamine

2026 Sebastian Baranyi Nicholls

Major depressive disorder (MDD) is a leading cause of disability worldwide, with nearly one-third remaining treatment-resistant. Chronic stress is a major risk factor for MDD, whereas acute stress is adaptive and mediated by hypothalamic-pituitary-adrenal axis activation. Ketamine produces rapid antidepressant effects, partly through mammalian target of rapamycin complex 1 (mTORC1) signalling,...

DOI: 10.22215/etd/2026-17222 (opens in new tab) Ketamine Excitatory postsynaptic potential Antidepressant Fight-or-flight response +7

Challenges of enrolling participants with alcohol and opioid use disorders in the emergency department for clinical trials of ketamine: The experience from two randomized controlled trials.

General Hospital Psychiatry 2026 Peter R. Chai, E Lee, M A Hasdianda et al.

Application of psychedelics including ketamine may be important adjuncts in the treatment of alcohol and opioid use disorders. Most patients with alcohol or opioid use disorder (AUD/OUD) may present to the emergency department (ED) seeking care both for substance use and associated complaints. Understanding safety and preliminary efficacy of ketamine and other psychedelics to improve the care...

L-tetrahydropalmatine attenuates ketamine reward effect via modulating the miR-27a-3p/MAP2K4 axis.

Frontiers in Genetics 2026 Yan Du, Xing-Cui Gao, Qing Ma et al.

Ketamine (KET) addiction has already been a serious problem all over the world, which could induce neurological and psychological harm. Levo-tetrahydropalmatine (l-THP), a major alkaloid extracted from the Chinese medicinal plants Corydalis and Stephania, has been shown to attenuate ketamine (KET) induced conditioned place preference (CPP) in rats. Nevertheless, the precise mechanism remains...

DOI: 10.3389/fgene.2026.1701742 (opens in new tab) Full text (opens in new tab) Bdnf-trkb L-tetrahydropalmatine Map2k4 Mir-27a-3p +1

Rethinking the Treatment-Resistant Depression.

Advances in experimental medicine and biology 2026 Yunfei Tan, Kenji Hashimoto 1 citation

Treatment-resistant depression (TRD) affects about one-third of people with major depression and leads to higher suicide rates, impaired functioning, and increased healthcare use. Originally defined as nonresponse to tricyclic antidepressants, TRD now encompasses inadequate response to multiple antidepressant classes, psychotherapy, and neuromodulation. Inconsistent criteria-varying by agency,...

Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2026 Yanhong Li, Kuangyu Zhao, Peipei Cao et al.

Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...

Bolus versus Continuous Infusion of Esketamine for Prevention of Postpartum Depression After Caesarean Delivery: A Randomized, Double-Blind, Controlled Trial.

Drug Design, Development and Therapy 2026 Jie Yang, Qiqi Yan, Ting Zhang et al.

Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...

DOI: 10.2147/dddt.s601347 (opens in new tab) Full text (opens in new tab) Esketamine Administration route Caesarean section Postpartum depression

Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker.

Journal of Neuroendocrinology 2026 Hiroe Hu, Yoojin Lee, Alaina N Tillman et al. 1 citation

Arginine vasopressin (AVP) modulates stress responsivity and social-affective behaviors, but its role in mood and trauma-related disorders remains poorly defined due to challenges in peripheral measurement. This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a transdiagnostic sample of individuals...

Sex, drugs, and arousal-two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity.

Therapeutic Advances in Psychopharmacology 2026 Manfred Klöbl, Thomas Liebe, Gregor Dörl et al.

Ketamine, a well-established antidepressant and dissociative anesthetic, is also used recreationally in the club and chemsex scene. Survey and qualitative data suggest that while ketamine facilitates chemsex encounters, it diminishes the intensity of the sexual experience. To investigate this phenomenon from a neuroscientific perspective while considering ketamine's sex-specific effects. Two...

Sympathetic activation but not dissociation linked to ketamine's sustained antidepressant effect.

Therapeutic Advances in Psychopharmacology 2026 Veronika Andrashko, Tomáš Novák, Miloslav Kopecek et al.

Ketamine is a rapid-acting antidepressant with robust evidence, but unclear predictors of therapeutic response. Based on previous knowledge, hemodynamic parameters and acute altered state of consciousness have been hypothesized as potential correlates of subsequent antidepressant outcome. A post hoc analysis was performed using the data from an open-label study, in which 39 patients with...

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs.

Frontiers in Psychiatry 2026 Ngo Cheung 6 citations

Rapid-acting antidepressants show that mood can lift within hours when glutamatergic circuits shift from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity®) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a...

Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment-Resistant Depression.

Journal of Neuroscience Research 2026 Stephanie N Njau, Artemis Zavaliangos-Petropulu, Shantanu Joshi et al.

Ketamine has emerged as a highly effective intervention for treatment-resistant depression (TRD). Though it acts as a non-competitive antagonist of excitatory N-methyl-D-aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ-aminobutyric acid (GABA)-ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate...

Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience.

General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation

Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...

Mental health professionals' perspective on the use of esketamine in treatment-resistant depression and their motivation to adopt it: a Saudi cross-sectional study.

Frontiers in Psychiatry 2026 Ahmad H Almadani, Ayedh H Alghamdi, Gosay M Almazyad et al.

Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors. This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the...

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.

Frontiers in Psychiatry 2026 C M Diendorfer, C Bum, Ana Weidenauer et al.

Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...

DOI: 10.3389/fpsyt.2026.1766485 (opens in new tab) Full text (opens in new tab) Ketamine Depressive symptoms Glutamate Negative symptoms schizophrenia

Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women.

American Journal of Translational Research 2026 Ran Jing, Yuanyan Tu

To investigate the effects of single low-dose esketamine combined with patient-controlled intravenous analgesia (PCIA) on early postpartum depression symptoms and recovery quality in women undergoing cesarean section. This prospective, randomized, controlled study enrolled 136 women scheduled for elective cesarean section, who were randomly assigned in a 1:1 ratio to the study group (esketamine...

DOI: 10.62347/euok7911 (opens in new tab) Full text (opens in new tab) Esketamine Low dose Cesarean section Patient-controlled intravenous analgesia +1

Ketamine treatment alleviates suicide ideation in high-risk populations: a systematic review and meta-analysis

Epidemiology and Psychiatric Sciences 2026 Wen Tang, Wei-Wei Jiang, Wen-Qian Que et al.

Abstract Aims To synthesize the available experimental study evidence to estimate the effects of ketamine on suicide ideation (SI) in high-risk individuals. Methods We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Double-blind randomized controlled trials and open-label studies investigating...

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

General Hospital Psychiatry 2026 Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.

Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...

Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1-ErbB4 pathway.

Frontiers in Psychiatry 2026 Hang Yu, Yuqiong Zhu, Jie Wang et al.

Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators...